What did @mel.mom.glp1.humor actually say?
Melissa, a 38-year-old who has been on GLP-1 medications for about six or seven months, claims she experienced a "skin sensitivity, almost sunburn-like feeling" while on semaglutide (Wegovy) at a dose she describes as "1.7," and that the same sensation returned on tirzepatide (Zepbound) after about five weeks at 5mg. She calls this "super rare" and says it is caused by the medication itself. She is not imagining things, and she is right to flag it. But her framing of why it happens, and how rare it actually is, deserves a closer look.
To be clear about what she is describing: localized, burning, or hypersensitive skin that feels like sunburn without visible injury. She places it on the right side of her arm. She stopped Wegovy over this and is now noticing it recurring on Zepbound.
Does the science back this up?
Yes, with important caveats. Peripheral neuropathy and cutaneous hypersensitivity have been reported in patients on GLP-1 receptor agonists, though the picture is complicated. A 2023 pharmacovigilance analysis published in Drug Safety (Faillie et al.) identified neurological adverse events including paresthesia and dysesthesia in GLP-1 agonist users, though causality was not firmly established. Separately, semaglutide has been associated with a condition called non-arteritic anterior ischemic optic neuropathy in a 2024 study in JAMA Ophthalmology (Hathaway et al.), which raised broader questions about GLP-1 drugs and nerve-related effects.
More relevant here: injection site reactions, including localized warmth and hypersensitivity, are documented in the official prescribing information for both Wegovy and Zepbound. However, a diffuse "sunburn-like" sensation on a body part away from the injection site is less clearly categorized. Some users report allodynia, where normal touch feels painful, which has been documented anecdotally but lacks large controlled-trial data specific to these agents.
What did they get wrong (or right)?
She gets credit for noticing a real pattern and not dismissing herself. The symptom she describes is plausible and has biological pathways worth taking seriously. GLP-1 receptors are expressed in peripheral neurons, and there is legitimate scientific interest in how these drugs interact with the nervous system beyond the gut and pancreas.
Where she oversimplifies: calling this "caused by this" as though the mechanism is settled is not accurate. The precise pathway from GLP-1 agonism to localized skin hypersensitivity is not established in peer-reviewed literature. It could be the drug. It could be rapid weight loss altering nerve function. It could be nutritional changes that accompany significant caloric restriction on GLP-1 therapy, such as B12 or thiamine changes, which are known to affect peripheral nerve sensation (Grunert et al., 2022, Nutrients). Calling the cause confirmed when it is not is worth flagging.
She also describes her Wegovy dose as "1.7," which does not correspond to any approved dosing increment for semaglutide. The standard titration goes 0.25, 0.5, 1.0, 1.7, 2.4 mg. The 1.7mg dose is a real step in the approved schedule, so this is likely accurate, not a red flag.
What should you actually know?
If you are on a GLP-1 medication and experience new burning, hypersensitive, or sunburn-like skin sensations that are not at the injection site, that warrants a conversation with your prescriber. This is not a reason to panic, but it is also not something to dismiss as psychological or unrelated to the drug.
A few things worth knowing before you spiral in the comments section. First, skin and nerve symptoms during rapid weight loss are not always drug-related. Rapid fat loss can compress or expose nerves that were previously cushioned. Second, nutritional deficiencies that emerge with reduced appetite, specifically B12, B1, and B6, can all produce peripheral neuropathy-type symptoms. These are testable and treatable. Third, the FDA adverse event reporting system (FAERS) does include sensory disturbance reports for both semaglutide and tirzepatide, though volume and causality analysis remain limited.
Do not stop a prescribed medication based on a TikTok video, including this one. Do report the symptom to your prescriber, ideally with notes on timing relative to your injection schedule and dose changes. That information actually matters clinically.